[1]. Hypnotics and Mortality in Idiopathic Pulmonary Fibrosis: Hospital and National Data-Based Analysis
Chest [巻]167 （2025年） [査読] 有
[2]. First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.
Lung cancer (Amsterdam, Netherlands) [巻]201 [頁]108109 （2025年） [査読] 有
[DOI] [3]. 皮膚科医に知ってほしい肺サルコイドーシス
皮膚科 [巻]6 [号]4 [頁]389 -394 （2024年） [査読] 有
[4]. Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study
BMC pulmonary medicine [巻]24 [号]1 [頁]495 （2024年） [査読] 有
[5]. 臨床薬理の進歩 2024（45号）
（2024年） [査読] 有
[6]. Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [頁]JCO2400278 （2024年） [査読] 有
[機関リポジトリ][7]. 静岡県の大学院大学・医科大学より「浜松医科大学臨床薬理学講座のご紹介」
静岡県医師会報 一般社団法人静岡県医師会 [号]1625 [頁]７ -９ （2023年） [査読] 有
[8]. A predictive model for acute exacerbation of idiopathic interstitial pneumonias.
European respiratory journal （2023年） [査読] 有
[DOI] [機関リポジトリ][9]. CD109 on Dendritic Cells Regulates Airway Hyperreactivity and Eosinophilic Airway Inflammation.
American journal of respiratory cell and molecular biology [巻]68 [号]2 [頁]201 -212 （2023年） [査読] 有
[DOI] [10]. Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer
J Cancer Res Clin Oncol [巻]149 [号]7 [頁]2963 -2974 （2023年） [査読] 有
[11]. Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancer.
Global health & medicine [巻]4 [号]6 [頁]301 -308 （2022年） [査読] 有
[DOI] [12]. A Case of Pulmonary Hypertension Associated with Diffuse Panbronchiolitis that Improved with Erythromycin and Home Oxygen Therapy.
Internal medicine (Tokyo, Japan) （2022年） [査読] 有
[DOI] [13]. Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study.
Emerging microbes & infections [巻]12 [号]1 [頁]2155250 （2022年） [査読] 有
[DOI] [14]. Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume.
European respiratory journal [巻]60 [号]6 （2022年） [査読] 有
[DOI] [15]. Prognostic significance of radiological pleuroparenchymal fibroelastosis in complex lung disease: a multicentre retrospective cohort study.
Thorax （2022年） [査読] 有
[DOI] [16]. Clinical practice of high-flow nasal cannula therapy in COVID-19 pandemic era: a cross-sectional survey of respiratory physicians.
Respiratory investigation [巻]60 [号]6 [頁]779 -786 （2022年） [査読] 有
[DOI] [17]. Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases.
BMC pulmonary medicine [巻]22 [号]1 [頁]387 （2022年） [査読] 有
[DOI] [18]. Cerebral Blood Deoxygenation by a Postural Change Detected by Near-Infrared Spectroscopy Has a Close Association with Cerebral Infarction.
Brain sciences [巻]12 [号]10 （2022年） [査読] 有
[DOI] [19]. Effect of Hypoxia on Pulmonary Endothelial Cells from Bleomycin-Induced Pulmonary Fibrosis Model Mice.
International journal of molecular sciences [巻]23 [号]16 （2022年） [査読] 有
[DOI] [20]. Associations of serum long-chain fatty acids with multiple organ involvement in patients with sarcoidosis.
BMC pulmonary medicine [巻]22 [号]1 [頁]290 （2022年） [査読] 有
[DOI] [21]. Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer.
Journal of cancer research and clinical oncology （2022年） [査読] 有
[DOI] [22]. Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study.
Journal of pharmacological sciences [巻]149 [号]2 [頁]60 -65 （2022年） [査読] 有
[DOI] [23]. Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis.
Respiratory research [巻]23 [号]1 [頁]142 （2022年） [査読] 有
[DOI] [24]. Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium.
BMC pulmonary medicine [巻]22 [号]1 [頁]186 （2022年） [査読] 有
[DOI] [25]. Impact of end-of-life respiratory modalities on quality of dying and death and symptom relief in patients with interstitial lung disease: a multicenter descriptive cross-sectional study.
Respiratory research [巻]23 [号]1 [頁]79 （2022年） [査読] 有
[DOI] [26]. Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis.
Thorax （2022年） [査読] 有
[DOI] [機関リポジトリ][27]. Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
BMC cancer [巻]22 [号]1 [頁]310 （2022年） [査読] 有
[DOI] [28]. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model.
Respiratory research [巻]23 [号]1 [頁]57 （2022年） [査読] 有
[DOI] [29]. Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).
Oncology and therapy （2022年） [査読] 有
[DOI] [30]. Involvement of autophagy in exacerbation of eosinophilic airway inflammation in a murine model of obese asthma.
Autophagy [頁]1 -13 （2022年） [査読] 有
[DOI] [31]. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [巻]40 [号]2 [頁]180 -188 （2022年） [査読] 有
[DOI] [32]. Multiple organ infarction caused by aortic thrombus in a lung cancer patient with the mutation.
Respiratory medicine case reports [巻]36 [頁]101608 （2022年） [査読] 有
[DOI] [33]. Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study.
Therapeutic advances in chronic disease [巻]13 [頁]20406223221108395 （2022年） [査読] 有
[DOI] [34]. Trimethoprim-sulfamethoxazole induced eosinophilic pneumonia: A case report.
Respiratory medicine case reports [巻]37 [頁]101632 （2022年） [査読] 有
[DOI] [35]. Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream.
Chemical & pharmaceutical bulletin [巻]70 [号]4 [頁]277 -282 （2022年） [査読] 有
[DOI] [36]. Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer.
Cancer Immunol. Immunother. [巻]71 [号]1 [頁]203 -217 （2022年） [査読] 有
[DOI] [37]. EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
JTO clinical and research reports [巻]3 [号]1 [頁]100264 （2022年） [査読] 有
[DOI] [38]. Transient leukocytopenia following combination therapy for COVID-19.
Respiratory investigation [巻]60 [号]1 [頁]158 -161 （2022年） [査読] 有
[DOI] [39]. Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report.
JTO clinical and research reports [巻]3 [号]1 [頁]100263 （2022年） [査読] 有
[DOI] [40]. Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy.
BMC pulmonary medicine [巻]21 [号]1 [頁]409 （2021年） [査読] 有
[DOI] [41]. Clinical Significance of Cold-Inducible RNA-Binding Protein in Idiopathic Pulmonary Fibrosis.
Chest [巻]160 [号]6 [頁]2149 -2157 （2021年） [査読] 有
[DOI] [機関リポジトリ][42]. Response.
Chest [巻]160 [号]6 [頁]e683 -e685 （2021年） [査読] 有
[DOI] [43]. BALT(気管支関連リンパ組織)
呼吸器内科 (有)科学評論社 [巻]40 [号]6 [頁]622 -625 （2021年） [査読] 無
[44]. Radiological pleuroparenchymal fibroelastosis-like lesion in idiopathic interstitial pneumonias.
Respiratory research [巻]22 [号]1 [頁]290 （2021年） [査読] 有
[DOI] [45]. Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis.
Respiratory investigation [巻]59 [号]6 [頁]827 -836 （2021年） [査読] 有
[DOI] [機関リポジトリ][46]. MET Amplification and Efficacy of Nivolumab in Patients With NSCLC.
JTO clinical and research reports [巻]2 [号]11 [頁]100239 （2021年） [査読] 有
[DOI] [47]. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis.
BMC pulmonary medicine [巻]21 [号]1 [頁]309 （2021年） [査読] 有
[DOI] [48]. Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis.
Scientific reports [巻]11 [号]1 [頁]18579 （2021年） [査読] 有
[DOI] [49]. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology [巻]32 [号]9 [頁]1137 -1147 （2021年） [査読] 有
[DOI] [50]. Diagnostic and prognostic significance of serum angiopoietin-1 and -2 concentrations in patients with pulmonary hypertension.
Scientific reports [巻]11 [号]1 [頁]15502 （2021年） [査読] 有
[DOI] [51]. Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas.
Scientific reports [巻]11 [号]1 [頁]14999 （2021年） [査読] 有
[DOI] [52]. Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.
BMC cancer [巻]21 [号]1 [頁]832 （2021年） [査読] 有
[DOI] [53]. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
BMC pulmonary medicine [巻]21 [号]1 [頁]221 （2021年） [査読] 有
[DOI] [54]. Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma.
Translational lung cancer research [巻]10 [号]7 [頁]3236 -3250 （2021年） [査読] 有
[DOI] [55]. Omeprazole suppresses endothelial calcium response and eNOS Ser1177 phosphorylation in porcine aortic endothelial cells.
Molecular biology reports [巻]48 [号]7 [頁]5503 -5511 （2021年） [査読] 有
[DOI] [機関リポジトリ][56]. Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-β and the Ubiquitin-Proteasome Pathway.
International journal of molecular sciences [巻]22 [号]11 （2021年） [査読] 有
[DOI] [57]. カルボプラチンに伴う悪心・嘔吐に対するオランザピン併用制吐療法の確立
臨床薬理の進歩 (公財)臨床薬理研究振興財団 [号]42 [頁]85 -92 （2021年） [査読] 有
[58]. Prognostic significance of peripheral blood monocyte and neutrophil counts in rheumatoid arthritis-associated interstitial lung disease.
Respiratory medicine [巻]182 [頁]106420 （2021年） [査読] 有
[DOI] [59]. Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study.
Scientific reports [巻]11 [号]1 [頁]9120 （2021年） [査読] 有
[DOI] [60]. Simple method for detecting idiopathic interstitial pneumonias by measuring vertical lung length on chest X-ray.
Scientific reports [巻]11 [号]1 [頁]7669 （2021年） [査読] 有
[DOI] [61]. Prognostic and Clinical Value of Cluster Analysis in Idiopathic Pleuroparenchymal Fibroelastosis Phenotypes.
Journal of clinical medicine [巻]10 [号]7 （2021年） [査読] 有
[DOI] [62]. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial.
Respirology (Carlton, Vic.) [巻]26 [号]4 [頁]370 -377 （2021年） [査読] 有
[DOI] [63]. Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers.
British journal of clinical pharmacology [巻]87 [号]4 [頁]1903 -1911 （2021年） [査読] 有
[DOI] [64]. Conventional type 2 lung dendritic cells are potent inducers of follicular helper T cells in the asthmatic lung.
Allergology international : official journal of the Japanese Society of Allergology （2021年） [査読] 有
[DOI] [65]. Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis
LUNG （2021年） [査読] 有
[DOI] [66]. Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study
THORAX [巻]76 [号]3 [頁]248 -255 （2021年） [査読] 有
[DOI] [67]. Clinical Significance of Interstitial Lung Disease and Its Acute Exacerbation in Microscopic Polyangiitis.
Chest. （2021年） [査読] 有
[DOI] [機関リポジトリ][68]. Pneumothorax in Patients with Idiopathic Pleuroparenchymal Fibroelastosis: Incidence, Clinical Features, and Risk Factors
RESPIRATION [巻]100 [号]1 [頁]19 -26 （2021年） [査読] 有
[DOI] [69]. Erlotinib and bevacizumab in elderly patients >= 75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations
INVESTIGATIONAL NEW DRUGS [巻]39 [号]1 [頁]210 -216 （2021年） [査読] 有
[DOI] [機関リポジトリ][70]. Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Clin Transl Oncol [巻]23 [号]2 [頁]418 -423 （2021年） [査読] 有
[DOI] [71]. Cluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival
BMC PULMONARY MEDICINE [巻]21 [号]1 （2021年） [査読] 有
[DOI] [72]. Subcutaneous injection of interferon gamma therapy could be useful for anti-IFN-gamma autoantibody associated disseminated nontuberculous mycobacterial infection
JOURNAL OF INFECTION AND CHEMOTHERAPY [巻]27 [号]2 [頁]373 -378 （2021年） [査読] 有
[DOI] [機関リポジトリ][73]. Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receivingantifibrotictherapy
RESPIROLOGY [巻]26 [号]2 [頁]171 -179 （2021年） [査読] 無
[DOI] [機関リポジトリ][74]. Verification of a cocktail approach for quantitative drug-drug interaction assessment: a comparative analysis between the results of a single drug and a cocktail drug
Xenobiotica [巻]51 [号]4 [頁]404 -412 （2021年） [査読] 有
[75]. Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
Cancer treatment and research communications [巻]29 [頁]100493 （2021年） [査読] 有
[DOI] [76]. Prediction of the Area under the Curve Using Limited-Point Blood Sampling in a Cocktail Study to Assess Multiple CYP Activities.
Biological & pharmaceutical bulletin [巻]44 [号]6 [頁]762 -770 （2021年） [査読] 有
[DOI] [77]. Metformin reduces pleural fibroelastosis by inhibition of extracellular matrix production induced by CD90-positive myofibroblasts.
American journal of translational research [巻]13 [号]11 [頁]12318 -12337 （2021年） [査読] 有
[78]. Predictors for bronchoalveolar lavage recovery failure in diffuse parenchymal lung disease
SCIENTIFIC REPORTS [巻]11 [号]1 （2021年） [査読] 有
[DOI] [79]. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
BMC CANCER [巻]21 [号]1 （2021年） [査読] 有
[DOI] [80]. Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians' View
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT [巻]60 [号]5 [頁]933 -940 （2020年） [査読] 有
[DOI] [機関リポジトリ][81]. Leucine-Rich alpha(2)-Glycoprotein as a Potential Biomarker for Immune-related Colitis After Anti-PD-L1 Therapy: A Report of a Case Series
CLINICAL LUNG CANCER [巻]21 [号]6 [頁]E516 -E522 （2020年） [査読] 有
[DOI] [機関リポジトリ][82]. Influenza A virus enhances ciliary activity and mucociliary clearance via TLR3 in airway epithelium
RESPIRATORY RESEARCH [巻]21 [号]1 （2020年） [査読] 有
[DOI] [83]. Development of a novel T cell-oriented vaccine using CTL/Th-hybrid epitope long peptide and biodegradable microparticles, against an intracellular bacterium
MICROBIOLOGY AND IMMUNOLOGY [巻]64 [号]10 [頁]666 -678 （2020年） [査読] 有
[DOI] [84]. Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data
CANCER SCIENCE [巻]111 [号]10 [頁]3705 -3713 （2020年） [査読] 有
[DOI] [85]. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer
JAMA NETWORK OPEN [巻]3 [号]9 （2020年） [査読] 有
[DOI] [86]. Disease course and prognosis of pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis
RESPIRATORY MEDICINE [巻]171 （2020年） [査読] 有
[DOI] [機関リポジトリ][87]. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE [巻]14 （2020年） [査読] 有
[DOI] [88]. Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study
JOURNAL OF THORACIC ONCOLOGY [巻]15 [号]8 [頁]1317 -1327 （2020年） [査読] 有
[DOI] [機関リポジトリ][89]. Propensity score analysis of overall l survival between first- and second-generation EGFR-TKIs using real-world data.
Cancer Sci [巻]111 [号]10 [頁]3705 -3713 （2020年） [査読] 有
[90]. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis
RESPIROLOGY [巻]25 [号]7 [頁]743 -749 （2020年） [査読] 有
[DOI] [機関リポジトリ][91]. Pneumothorax in connective tissue disease-associated interstitial lung disease
PLOS ONE [巻]15 [号]7 （2020年） [査読] 有
[DOI] [92]. Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE [巻]14 （2020年） [査読] 有
[DOI] [93]. Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer
LUNG CANCER [巻]143 [頁]47 -54 （2020年） [査読] 有
[DOI] [94]. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer
LUNG CANCER [巻]141 [頁]21 -31 （2020年） [査読] 有
[DOI] [95]. Pulse oximetric saturation to fraction of inspired oxygen (SpO(2)/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE [巻]14 （2020年） [査読] 有
[DOI] [96]. Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia (vol 9, 18750, 2019)
SCIENTIFIC REPORTS [巻]10 [号]1 （2020年） [査読] 有
[DOI] [97]. CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer
ONCOIMMUNOLOGY [巻]9 [号]1 （2020年） [査読] 有
[DOI] [98]. CD248 and integrin alpha-8 are candidate markers for differentiating lung fibroblast subtypes
BMC PULMONARY MEDICINE [巻]20 [号]1 （2020年） [査読] 有
[DOI] [99]. Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia.
Scientific reports [巻]9 [号]1 [頁]18750 （2019年） [査読] 有
[DOI] [100]. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD
RHEUMATOLOGY [巻]58 [号]12 [頁]2143 -2152 （2019年） [査読] 有
[DOI] [101]. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Cancer [巻]125 [号]22 [頁]4076 -4083 （2019年） [査読] 有
[DOI] [102]. Simultaneous Occurrence of Sarcoidosis and Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis in a Patient with Lung Cancer.
Internal medicine (Tokyo, Japan) [巻]58 [号]22 [頁]3299 -3304 （2019年） [査読] 有
[DOI] [103]. Synchronous Occurrence of Bazex Syndrome and Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Patient with Lung Cancer.
Internal medicine (Tokyo, Japan) [巻]58 [号]22 [頁]3267 -3271 （2019年） [査読] 無
[DOI] [104]. Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases.
Respiratory medicine [巻]159 [頁]105811 （2019年） [査読] 有
[DOI] [105]. Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
Respiratory investigation [巻]57 [号]6 [頁]552 -560 （2019年） [査読] 有
[DOI] [106]. Transient Laterality of Cerebral Oxygenation Changes in Response to Head-of-Bed Manipulation in Acute Ischemic Stroke.
Journal of clinical medicine [巻]8 [号]10 （2019年） [査読] 有
[DOI] [107]. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis.
Respirology (Carlton, Vic.) （2019年） [査読] 有
[DOI] [108]. Body composition changes successfully classify prognosis in patients with mycobacterium avium complex lung disease.
The Journal of infection [巻]79 [号]4 [頁]341 -348 （2019年） [査読] 有
[DOI] [109]. Effect of rifampicin and clarithromycin on the CYP3A activity in patients with complex.
Journal of thoracic disease [巻]11 [号]9 [頁]3814 -3821 （2019年） [査読] 有
[DOI] [110]. Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis.
Respirology (Carlton, Vic.) [巻]24 [号]8 [頁]792 -798 （2019年） [査読] 有
[DOI] [111]. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
The Journal of rheumatology [巻]46 [号]8 [頁]935 -942 （2019年） [査読] 有
[DOI] [112]. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Lung cancer (Amsterdam, Netherlands) ELSEVIER [巻]134 [頁]202 -209 （2019年） [査読] 有
[DOI] [113]. Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis.
Scientific reports [巻]9 [号]1 [頁]10484 （2019年） [査読] 有
[DOI] [114]. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Cancer chemotherapy and pharmacology [巻]84 [号]1 [頁]147 -153 （2019年） [査読] 有
[DOI] [115]. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Investigational new drugs [巻]37 [号]3 [頁]531 -537 （2019年） [査読] 有
[DOI] [116]. Physiological and morphological differences of airways between COPD and asthma-COPD overlap.
Scientific reports [巻]9 [号]1 [頁]7818 （2019年） [査読] 有
[DOI] [117]. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
The Journal of rheumatology [巻]46 [号]5 [頁]509 -517 （2019年） [査読] 有
[DOI] [118]. Methotrexate-associated Lymphoproliferative Disorder with Diffuse Ground-Glass Opacities.
American journal of respiratory and critical care medicine [巻]199 [号]8 [頁]1031 -1033 （2019年） [査読] 有
[DOI] [119]. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype.
Journal of pharmacological sciences [巻]139 [号]4 [頁]361 -366 （2019年） [査読] 有
[DOI] [120]. Preparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and Evaluation of Their Clinical Palatability.
Chemical & pharmaceutical bulletin [巻]67 [号]2 [頁]112 -119 （2019年） [査読] 有
[DOI] [121]. Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
Chemical & pharmaceutical bulletin [巻]67 [号]6 [頁]540 -545 （2019年） [査読] 有
[DOI] [122]. Clinical features of three-dimensional computed tomography-based radiologic phenotypes of chronic obstructive pulmonary disease.
International journal of chronic obstructive pulmonary disease [巻]14 [頁]1333 -1342 （2019年） [査読] 有
[DOI] [123]. Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial.
Journal of asthma and allergy [巻]12 [頁]253 -261 （2019年） [査読] 有
[DOI] [124]. The Prediction of the Area under the Curve and Clearance of Midazolam from Single-Point Plasma Concentration and Urinary Excretion in Healthy Volunteers.
Biological & pharmaceutical bulletin [巻]42 [号]9 [頁]1590 -1595 （2019年） [査読] 有
[DOI] [125]. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
International journal of chronic obstructive pulmonary disease [巻]14 [頁]1867 -1877 （2019年） [査読] 有
[DOI] [126]. Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis.
Chronic respiratory disease [巻]16 [頁]1479972318809476 （2019年） [査読] 有
[DOI] [127]. Frequency and clinical relevance of anti-cyclic citrullinated peptide antibody in idiopathic interstitial pneumonias
RESPIRATORY MEDICINE [巻]154 [頁]102 -108 （2019年） [査読] 有
[DOI] [128]. Correlation of the modified Medical Research Council dyspnea scale with airway structure assessed by three-dimensional CT in patients with chronic obstructive pulmonary disease.
Respiratory medicine [巻]146 [頁]76 -80 （2019年） [査読] 有
[DOI] [129]. Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non-Small Cell Lung Cancer After Nivolumab Therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) [巻]45 [号]2 [頁]125 -131
[DOI]